BeOne Medicines (NASDAQ:ONC) CFO Aaron Rosenberg Sells 1,157 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CFO Aaron Rosenberg sold 1,157 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $312.71, for a total value of $361,805.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Aaron Rosenberg also recently made the following trade(s):

• On Thursday, June 11th, Aaron Rosenberg sold 631 shares of BeOne Medicines stock. The shares were sold at an average price of $257.74, for a total value of $162,633.94.

BeOne Medicines Trading Up 1.4%

NASDAQ ONC opened at $327.53 on Thursday. The stock has a market capitalization of $35.94 billion, a price-to-earnings ratio of 73.27 and a beta of 0.49. The stock’s 50 day moving average price is $294.53 and its two-hundred day moving average price is $308.67. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $253.95 and a 52 week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.65. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. As a group, analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 earnings per share for the current fiscal year.

BeOne Medicines News Roundup

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q2 earnings surpassed expectations: BeOne Medicines reported adjusted earnings of $2.05 per share, well above the $1.40 analyst consensus. The result strengthens the investment case by demonstrating better-than-expected profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: Revenue outlook exceeded forecasts: Management projected fiscal 2026 revenue of $6.6 billion to $6.8 billion, compared with Wall Street’s $6.5 billion expectation. The guidance suggests continued momentum across the company’s oncology portfolio. BeOne Medicines Q2 metrics
• Positive Sentiment: Pipeline progress provided additional support: BeOne’s liver-cancer bispecific received a UK Innovation Passport, potentially helping accelerate development and regulatory engagement for the candidate. BeOne lands UK Innovation Passport
• Neutral Sentiment: Analyst sentiment remains favorable: Recent coverage maintained predominantly Buy or Overweight ratings, with a reported consensus price target of approximately $394, although the stock’s elevated valuation leaves expectations high.
• Neutral Sentiment: Insider transactions were sales for tax purposes: CFO Aaron Rosenberg sold 1,157 shares worth about $362,000, while SVP Chan Henry Lee sold 1,044 shares worth approximately $338,000. Both transactions were explicitly tied to tax withholding on vested equity awards, reducing their significance as a bearish signal. BeOne CFO SEC filing

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. raised their target price on shares of BeOne Medicines from $415.00 to $425.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Zacks Research cut shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 3rd. Morgan Stanley reissued an “overweight” rating and set a $395.00 price target on shares of BeOne Medicines in a research report on Thursday, May 7th. Nomura upgraded shares of BeOne Medicines to a “strong-buy” rating in a research note on Monday, July 27th. Finally, Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 18th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $394.00.

Hedge Funds Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently made changes to their positions in ONC. BNP Paribas Financial Markets grew its position in shares of BeOne Medicines by 100.6% in the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after acquiring an additional 97,244 shares during the period. SEB Asset Management AB acquired a new stake in BeOne Medicines in the 1st quarter valued at about $16,653,000. Renaissance Technologies LLC bought a new position in BeOne Medicines during the first quarter worth about $19,438,000. Capital International Sarl increased its position in BeOne Medicines by 2.7% during the fourth quarter. Capital International Sarl now owns 152,515 shares of the company’s stock worth $46,336,000 after buying an additional 3,956 shares during the last quarter. Finally, Slow Capital Inc. increased its position in BeOne Medicines by 51.5% during the fourth quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock worth $8,294,000 after buying an additional 9,280 shares during the last quarter. 48.55% of the stock is owned by institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.